ライフサイエンスコーパス: co-inhibitory

1 Co-inhibitory and checkpoint molecules suppress T cell f

2 lasmodium control and that crosstalk between co-inhibitory and co-stimulatory pathways in pathogen-sp

3 Modulation of co-inhibitory and co-stimulatory receptors of the immune

4 D-L1; encoded by the CD274 gene), is a major co-inhibitory checkpoint signaling that controls T cell

5 e where it can exert both co-stimulatory and co-inhibitory functions.

6 Co-inhibitory immune receptors can contribute to T cell

7 elitis (with programmed cell-death-1 and the co-inhibitory ligand CD276 driving the tolerogenic respo

8 , a member of the B7 family of costimulatory/co-inhibitory ligands expressed by both malignant cells

9 IL)-10 production, and overexpression of the co-inhibitory ligands programmed death ligand 1 (PD-L1)

10 h cancer cells upregulating MHC class II and co-inhibitory ligands, potentially driving Treg and Tex

11 Tumor expression of immune co-inhibitory ligands, such as PD-L1 and Galectin-9, hav

12 imately 50% of Tc17 cells also expressed the co-inhibitory molecule CTLA-4, and only a minority (<20%

13 nner, induce differential co-stimulatory and co-inhibitory molecule expression, and influence cytokin

14 Co-inhibitory molecule PD-1, among others, distinguish C

15 dent upon sustained T cell expression of the co-inhibitory molecule PD-1.

16 the first genetic evidence that BTN2A2 is a co-inhibitory molecule that modulates T cell-mediated im

17 tion to assess the expression pattern of the co-inhibitory molecule TIGIT together with PD-1, BTLA, T

18 cDC1s, shown by their specific expression of co-inhibitory molecules and cytokines, critically contri

19 ciated with high expression levels of T-cell co-inhibitory molecules and elevated interferon signalin

20 Interestingly, the co-inhibitory molecules cytotoxic T lymphocyte antigen-4

21 d with those derived from co-stimulatory and co-inhibitory molecules implicated in the cell-intrinsic

22 summarizes recent data regarding the role of co-inhibitory molecules in the control of T(reg) cell fu

23 Although conditional deletion of these co-inhibitory molecules on B cells had little or no effe

24 Co-inhibitory molecules play a major role in modulating

25 ranscriptional signature, including multiple co-inhibitory molecules such as PD-1, TIM-3, TIGIT and L

26 A list of T-cell co-inhibitory molecules was also downregulated.

27 1) is highly coexpressed with genes encoding co-inhibitory molecules, indicating that it might be a p

28 CR7(+) DCs expressed both co-stimulatory and co-inhibitory molecules, which may underlie their capaci

29 PD-L1(+) DC, MDSC, TAM and Treg, as well as co-inhibitory molecules-double-positive, severely exhaus

30 lves a complex network of co-stimulatory and co-inhibitory molecules.

31 While therapies targeting the co-inhibitory or immune checkpoint receptors PD-1 and CT

32 al data indicated that TIM3 functioned as a 'co-inhibitory' or 'checkpoint' receptor, but due to the

33 d side effects, suggesting the importance of co-inhibitory pathway for both prevention of autoimmunit

34 ptor and its ligands, PD-L1 and PD-L2, are a co-inhibitory pathway that contributes to the negative r

35 will focus on the role of co-stimulatory and co-inhibitory pathways in two systemic (systemic lupus e

36 ific responses (secondary endpoint), but not co-inhibitory pathways or Treg, and reduces protumoral s

37 which is a large array of co-stimulatory and co-inhibitory pathways that modulate the host response.

38 these might be increased by blocking T-cell co-inhibitory pathways, such as preventing interaction b

39 ogated following coordinate blockade of PD-1 co-inhibitory pathways, which are also upregulated durin

40 incident with selective upregulation of CD85 co-inhibitory pathways.

41 12 application with systemic blockade of the co-inhibitory receptor CTLA-4 on T cells led to tumor er

42 Mice lacking the co-inhibitory receptor cytotoxic T lymphocyte antigen-4

43 D8(+) T-cells and NK-cells display increased co-inhibitory receptor expression and decreased cytotoxi

44 tting of chronic diseases where constitutive co-inhibitory receptor expression on T cells dampens eff

45 r domain mediate binding to the adhesion and co-inhibitory receptor P-selectin glycoprotein ligand-1

46 We apply this technology to tune the T-cell co-inhibitory receptor PD-1 and to explore how antigen e

47 n the crosstalk with microglia cells and the co-inhibitory receptor PD-1, the main target of currentl

48 une restoration potential of blockade of the co-inhibitory receptor programmed death 1 (PD-1) during

49 tes various immune responses by engaging the co-inhibitory receptor programmed death-1.

50 otentially other lymphoid co-stimulatory and co-inhibitory receptor proteins in governing microglial

51 e binding affinities of the PD-1-PD-L1/PD-L2 co-inhibitory receptor system, and discovered an unexpec

52 The next wave of co-inhibitory receptor targets that are being explored i

53 Our data thus implicate CD160 as a co-inhibitory receptor that delivers antigen-dependent s

54 effects of programmed cell death 1 (PD1), a co-inhibitory receptor that impairs T-cell function and

55 B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor that interacts with herpesvirus e

56 Tim-3 is a co-inhibitory receptor that is expressed on IFN-g-produc

57 The co-inhibitory receptor TIGIT suppresses excessive immune

58 we uncovered a nonclassical function of the co-inhibitory receptor TIGIT, wherein it not only limits

59 3 is part of a module that contains multiple co-inhibitory receptors (checkpoint receptors), which ar

60 co-stimulatory molecules (i.e., CD80, CD86), co-inhibitory receptors (PD-1, CTLA-4), the tyrosine pho

61 f cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules.

62 ggesting that a crosstalk exists between two co-inhibitory receptors and the two pairs of ligand-rece

63 s, we investigated whether disruption of the co-inhibitory receptors CTLA4 or PD-1 could restore CART

64 d by the constellation of co-stimulatory and co-inhibitory receptors expressed on the cell surface.

65 at occur in cancer, highlighting the role of co-inhibitory receptors in contributing to this process

66 n SIRPalpha(+) CD8(+) T cells, expression of co-inhibitory receptors is counterbalanced by expression

67 - and time-dependent programming of distinct co-inhibitory receptors rapidly recalibrates T cell acti

68 However, all co-inhibitory receptors share an ability to oppose activ

69 f CD57 and loss of CD28, with an increase in co-inhibitory receptors such as PD-1 and Tim-3.

70 In this regard, several co-inhibitory receptors that are preferentially expresse

71 checkpoints, co-stimulatory receptors and/or co-inhibitory receptors that control T cell function is

72 This has provided impetus to identify other co-inhibitory receptors that could be exploited to enhan

73 -domain molecule 3 (Tim-3), which are potent co-inhibitory receptors, and their persistent expression

74 a subtle increase in the expression of some co-inhibitory receptors, most notably PD-1 and TIM-3, am

75 Co-inhibitory receptors, such as CTLA-4 and PD-1, have a

76 on of multiple additional co-stimulatory and co-inhibitory receptors.

77 s exist to limit Akt activation by different co-inhibitory receptors.

78 s but potentially between co-stimulatory and co-inhibitory receptors.

79 ked by expression of interleukin (IL)-10 and co-inhibitory receptors.

80 prominent sites of synapsis initiation, and CO-inhibitory role(s) that limit CO number.

81 CD28-B7) with Lulizumab, which preserves the co-inhibitory signal (CTLA4-B7).

82 the recent advances in our understanding of co-inhibitory signaling and its potential clinical appli

83 Our test results further indicate that both co-inhibitory signaling pathways activated by B7 and PD-

84 presenting cells (APC) activates two central co-inhibitory signaling pathways to suppress T cell func

85 In addition to blocking co-inhibitory signals in secondary lymphoid organs, cyto

86 Here, we identified a critical role for the co-inhibitory SLAM family member 2B4 (CD244) in attenuat

87 lly, we sought to quantify the expression of co-inhibitory surface molecules PD-1, LAG3, and TIM3.

88 of agents targeting both co-stimulatory and co-inhibitory T cell receptors.